secwatch.observer — SEC 8-K summary
======================================

Issuer:     Design Therapeutics, Inc. (DSGN)
CIK:        0001807120
Form:       8-K
Filed at:   2022-05-09T23:59:59+00:00
Accession:  0000950170-22-008486
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Design Therapeutics Q1 net loss $13.3M; cash $371.2M; DT-216 Phase 1 underway
-----------------------------------------------------------------------------

- Net loss of $13.3M for Q1 2022; R&D expenses $8.8M, G&A $4.6M.
- Cash, cash equivalents and marketable securities of $371.2M as of March 31, 2022.
- DT-216 Phase 1 single-ascending dose trial in Friedreich ataxia patients; topline data expected H2 2022.
- DT-216 received FDA Fast Track designation for FA.
- Preclinical data for Fuchs endothelial corneal dystrophy GeneTAC molecules showed up to 99% reduction in toxic RNA foci.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807120/000095017022008486/0000950170-22-008486-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807120/000095017022008486/dsgn-20220509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-008486

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer